Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland...
- BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland
- Diabetes Week: investigating the immune basis of type 1 diabetes
- Everest Medicines to commercialise Calliditas’ Nefecon in Greater China and Singapore
- AstraZeneca’s Calquence shows superiority to chemotherapy in CLL
- Researchers discover new drug target in tuberculosis
Merck’s Keytruda secures expanded indications in US
The US Food and Drug Administration (FDA) has approved two indications for Merck’s Keytruda, expanding its application to the oncology market.
Fine-tuning checkpoint inhibitor use in triple-negative breast cancer
Despite the widespread use of checkpoint inhibitors (CPIs) in oncology, breast cancer is one indication where CPIs haven’t shown extensive clinical benefit to date.
Boehringer expands PROTAC drugs partnership with Dundee University
Boehringer Ingelheim has extended a collaboration with the University of Dundee in Scotland for the development of proteolysis targeting chimera (PROTAC) based drugs to treat cancer.
BMS’ Opdivo plus Yervoy for RCC to be available through NHS Scotland
Scotland’s healthcare pricing regulator the Scottish Medicines Consortium (SMC) has decided to fund Bristol Myers-Squibb (BMS)’s Opdivo (nivolumab) plus Yervoy (ipilimumab) for use in NHS Scotland for renal cell carcinoma (RCC) patients, who are previously untreated and considered to be of intermediate or poor prognostic risk.
Novel HER2 blockade treatments continue to show promise in third-line setting for metastatic breast cancer
Patients with HER2-positive metastatic breast cancer continue to need new treatment options.
Diabetes Week: investigating the immune basis of type 1 diabetes
Diabetes UK use its annual Diabetes Week to raise awareness, as well as funds for, among other things, crucial research into new treatments for diabetes. One largely neglected therapeutic approach the charity has invested in is repurposing immunotherapies from other autoimmune diseases for type 1 diabetes, linked with the immune system’s role in destroying pancreatic cells.
Everest Medicines to commercialise Calliditas’ Nefecon in Greater China and Singapore
Sweden-based Calliditas Therapeutics has announced that Everest Medicines will commercialise its IgA nephropathy (IgAN) drug Nefecon in Greater China, which encompasses China, Hong Kong, Macau and Taiwan, and Singapore.
What role is there for cannabis use in cancer care?
It is documented that up to 24% of oncology patients are currently using cannabis primarily for pain, nausea and to help to treat their cancer.
Maintenance olaparib trial brings hope to BRCA mutant pancreatic cancer patients
In pancreatic cancer, no targeted treatments for a biomarker selected population had been validated in a Phase III trial.
FDA advisory panel recommends TB Alliance’s tuberculosis drug
An advisory panel to the US Food and Drug Administration (FDA) has recommended the approval of TB Alliance’s investigational drug pretomanid in combination with bedaquiline and linezolid to treat drug-resistant tuberculosis.
Read our magazine
Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.